Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase

F H Ebetino, C N Roze, C E McKenna, B L Barnett, J E Dunford, R G G Russell, G E Mieling, M J Rogers

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Bisphosphonates, known for their effectiveness in the treatment of osteoporosis, inhibit bone resorption via mechanisms that involve binding to bone mineral and cellular effects on osteoclasts. The major molecular target of nitrogen-containing hisphosphonates (N-BPs) in osteoclasts is farnesyl diphosphate synthase (FPPS). N-BPs likely inhibit this enzyme by mimicking one or more of the natural isoprenoid lipid substrates (GPP/DMAPP and IPP) but the mode of inhibition is not established. The active site of FPPS comprises a subsite for each substrate. Kinetic studies with recombinant human FPPS indicate that both potent (risedronate) and weak (NE-58051) enzyme inhibitors compete with GPP for binding to FPPS, however, binding to this site does not completely explain the difference in potency of the two inhibitors, suggesting that a second binding site may also be a target of bisphosphonate inhibition. Using the docking software suite Autodock, we explored a dual inhibitor binding mode for recombinant human FPPS. Experimental support for dual binding is suggested by Dixon plots for the inhibitors. N-BPs may inhibit by binding to both the GPP and a second site with differences in potency at least partly arising from inhibition at the second site. (c) 2005 Published by Elsevier B.V.

Original languageEnglish
Pages (from-to)2679-2687
Number of pages9
JournalJournal of Organometallic Chemistry
Volume690
DOIs
Publication statusPublished - 2005

Keywords

  • bisphosphonate
  • farnesyl diphosphate synthase
  • docking
  • enzyme kinetics
  • dual site inhibition
  • risedronate
  • BONE-RESORPTION
  • PYROPHOSPHATE SYNTHASE
  • ISOPRENOID BIOSYNTHESIS
  • TRYPANOSOMA-BRUCEI
  • POTENTIAL ROUTE
  • IN-VIVO
  • INHIBITION
  • MECHANISM
  • ANALOGS
  • ENZYMES

Cite this

Ebetino, F. H., Roze, C. N., McKenna, C. E., Barnett, B. L., Dunford, J. E., Russell, R. G. G., ... Rogers, M. J. (2005). Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. Journal of Organometallic Chemistry, 690, 2679-2687. https://doi.org/10.1016/j.jorganchem.2005.03.005

Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. / Ebetino, F H ; Roze, C N ; McKenna, C E ; Barnett, B L ; Dunford, J E ; Russell, R G G ; Mieling, G E ; Rogers, M J .

In: Journal of Organometallic Chemistry, Vol. 690, 2005, p. 2679-2687.

Research output: Contribution to journalArticle

Ebetino, FH, Roze, CN, McKenna, CE, Barnett, BL, Dunford, JE, Russell, RGG, Mieling, GE & Rogers, MJ 2005, 'Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase', Journal of Organometallic Chemistry, vol. 690, pp. 2679-2687. https://doi.org/10.1016/j.jorganchem.2005.03.005
Ebetino, F H ; Roze, C N ; McKenna, C E ; Barnett, B L ; Dunford, J E ; Russell, R G G ; Mieling, G E ; Rogers, M J . / Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. In: Journal of Organometallic Chemistry. 2005 ; Vol. 690. pp. 2679-2687.
@article{300d9c9731a84b919364383f9a690b5d,
title = "Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase",
abstract = "Bisphosphonates, known for their effectiveness in the treatment of osteoporosis, inhibit bone resorption via mechanisms that involve binding to bone mineral and cellular effects on osteoclasts. The major molecular target of nitrogen-containing hisphosphonates (N-BPs) in osteoclasts is farnesyl diphosphate synthase (FPPS). N-BPs likely inhibit this enzyme by mimicking one or more of the natural isoprenoid lipid substrates (GPP/DMAPP and IPP) but the mode of inhibition is not established. The active site of FPPS comprises a subsite for each substrate. Kinetic studies with recombinant human FPPS indicate that both potent (risedronate) and weak (NE-58051) enzyme inhibitors compete with GPP for binding to FPPS, however, binding to this site does not completely explain the difference in potency of the two inhibitors, suggesting that a second binding site may also be a target of bisphosphonate inhibition. Using the docking software suite Autodock, we explored a dual inhibitor binding mode for recombinant human FPPS. Experimental support for dual binding is suggested by Dixon plots for the inhibitors. N-BPs may inhibit by binding to both the GPP and a second site with differences in potency at least partly arising from inhibition at the second site. (c) 2005 Published by Elsevier B.V.",
keywords = "bisphosphonate, farnesyl diphosphate synthase, docking, enzyme kinetics, dual site inhibition, risedronate, BONE-RESORPTION, PYROPHOSPHATE SYNTHASE, ISOPRENOID BIOSYNTHESIS, TRYPANOSOMA-BRUCEI, POTENTIAL ROUTE, IN-VIVO, INHIBITION, MECHANISM, ANALOGS, ENZYMES",
author = "Ebetino, {F H} and Roze, {C N} and McKenna, {C E} and Barnett, {B L} and Dunford, {J E} and Russell, {R G G} and Mieling, {G E} and Rogers, {M J}",
year = "2005",
doi = "10.1016/j.jorganchem.2005.03.005",
language = "English",
volume = "690",
pages = "2679--2687",
journal = "Journal of Organometallic Chemistry",
issn = "0022-328X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase

AU - Ebetino, F H

AU - Roze, C N

AU - McKenna, C E

AU - Barnett, B L

AU - Dunford, J E

AU - Russell, R G G

AU - Mieling, G E

AU - Rogers, M J

PY - 2005

Y1 - 2005

N2 - Bisphosphonates, known for their effectiveness in the treatment of osteoporosis, inhibit bone resorption via mechanisms that involve binding to bone mineral and cellular effects on osteoclasts. The major molecular target of nitrogen-containing hisphosphonates (N-BPs) in osteoclasts is farnesyl diphosphate synthase (FPPS). N-BPs likely inhibit this enzyme by mimicking one or more of the natural isoprenoid lipid substrates (GPP/DMAPP and IPP) but the mode of inhibition is not established. The active site of FPPS comprises a subsite for each substrate. Kinetic studies with recombinant human FPPS indicate that both potent (risedronate) and weak (NE-58051) enzyme inhibitors compete with GPP for binding to FPPS, however, binding to this site does not completely explain the difference in potency of the two inhibitors, suggesting that a second binding site may also be a target of bisphosphonate inhibition. Using the docking software suite Autodock, we explored a dual inhibitor binding mode for recombinant human FPPS. Experimental support for dual binding is suggested by Dixon plots for the inhibitors. N-BPs may inhibit by binding to both the GPP and a second site with differences in potency at least partly arising from inhibition at the second site. (c) 2005 Published by Elsevier B.V.

AB - Bisphosphonates, known for their effectiveness in the treatment of osteoporosis, inhibit bone resorption via mechanisms that involve binding to bone mineral and cellular effects on osteoclasts. The major molecular target of nitrogen-containing hisphosphonates (N-BPs) in osteoclasts is farnesyl diphosphate synthase (FPPS). N-BPs likely inhibit this enzyme by mimicking one or more of the natural isoprenoid lipid substrates (GPP/DMAPP and IPP) but the mode of inhibition is not established. The active site of FPPS comprises a subsite for each substrate. Kinetic studies with recombinant human FPPS indicate that both potent (risedronate) and weak (NE-58051) enzyme inhibitors compete with GPP for binding to FPPS, however, binding to this site does not completely explain the difference in potency of the two inhibitors, suggesting that a second binding site may also be a target of bisphosphonate inhibition. Using the docking software suite Autodock, we explored a dual inhibitor binding mode for recombinant human FPPS. Experimental support for dual binding is suggested by Dixon plots for the inhibitors. N-BPs may inhibit by binding to both the GPP and a second site with differences in potency at least partly arising from inhibition at the second site. (c) 2005 Published by Elsevier B.V.

KW - bisphosphonate

KW - farnesyl diphosphate synthase

KW - docking

KW - enzyme kinetics

KW - dual site inhibition

KW - risedronate

KW - BONE-RESORPTION

KW - PYROPHOSPHATE SYNTHASE

KW - ISOPRENOID BIOSYNTHESIS

KW - TRYPANOSOMA-BRUCEI

KW - POTENTIAL ROUTE

KW - IN-VIVO

KW - INHIBITION

KW - MECHANISM

KW - ANALOGS

KW - ENZYMES

U2 - 10.1016/j.jorganchem.2005.03.005

DO - 10.1016/j.jorganchem.2005.03.005

M3 - Article

VL - 690

SP - 2679

EP - 2687

JO - Journal of Organometallic Chemistry

JF - Journal of Organometallic Chemistry

SN - 0022-328X

ER -